Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The November 2002 monograph topics are adefovir dipivoxil, ximelagatran, agalsidase alfa and agalsidase beta, pemetrexed, and emtricitabine. The DUE is on adefovir dipivoxil.
Get full access to this article
View all access options for this article.
References
1.
Geodon and Geodon for Injection [package literature]. Pfizer Pharmaceuticals; June 2002.
2.
RichelsonE.Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry.1999; 60(suppl 10): 5–14.
3.
SeegerT.F.Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther.1995; 275: 101–13.
4.
TatsumiM.Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol.1999; 368: 277–83.
5.
SprouseJ.S.Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: Inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology.1999; 21: 622–31.
6.
WilnerK.D.Pharmacokinetics of intramuscular ziprasidone in healthy volunteers: Results from two controlled studies [abstract]. Schizophr Res.2001; 49(2, suppl): 255.
7.
MiceliJ.Use of population pharmacokinetic modeling to characterize the intramuscular pharmacokinetics of the novel antipsychotic agent ziprasidone in schizophrenic patients [abstract]. Schizophr Res.1999; 36(1-3): 289–90.
8.
ShadM.U.Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients [abstract]. Clin Pharmacol Ther.1999; 65(2): 171.
9.
WilnerK.D.Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol.2000; 49(suppl 1): 15S–20S.
10.
HamelinB.A.The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy.1998; 18: 9–15.
11.
CacciaS.Biotransformation of postclozapine antipsychotics: Pharmacological implications. Clin Pharmacokinet.2000; 38: 393–414.
12.
EversonG.The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol.2000; 49(suppl 1): 21S–6S.
13.
AweekaF.The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol.2000; 49(suppl 1): 27S–33S.
14.
MiceliJ.J.Single- and multiple- dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers. Br J Clin Pharmacol.2000; 49(suppl 1): 5S–13S.
15.
PrakashC.Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos.1997; 25: 863–72.
16.
PrakashC.Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol.2000; 49(suppl 1): 35S–42S.
17.
PfizerBriefing document for Zeldox capsules (ziprasidone HCl). FDA Psychopharmacological Drugs Advisory Committee. July 19, 2000.
18.
SwiftR.H.Validation of the behavioral activity rating scale (BARS)TM: A novel measure of activity in agitated patients. J Psych Res.2002; 36: 87–95.
19.
DanielD.G.Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology.2001; 155: 128–34.
20.
LesemM.D.Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry.2001; 62: 12–8.
21.
BrookS.Ziprasidone vs haloperidol in sequential IM/oral treatment of acute schizophrenia [abstract]. Schizophr Res.2002; 53(3, suppl): 181.
22.
SwiftR.H.A comparison of intramuscular ziprasidone with IM haloperidol [abstract]. Schizophr Res.1999; 36(1-3): 298.
23.
BrookS.The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute, nonorganic psychosis [abstract]. Schizophr Res.1999; 36(1-3): 272.
24.
KeckP.E.JrThe efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psych.2000; 61(suppl 3): 4–9.
25.
BrookS.Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry.2000; 61: 933–41.
26.
BrookS.A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia. Human Psychopharmacol.2000; 15: 521–4.
27.
LaughrenT., GordonM.FDA background on Zeldox (ziprasidone hydrochloride capsules)Pfizer, Inc. Psychopharmacological Drugs Advisory Committee. Bethesda, MD: FDA; July 19, 2000.
28.
MiceliJ.J.IM ziprasidone and IM haloperidol have comparable effects on QTc at Cmax [abstract]. Philadelphia: 155th Annual Meeting of the American Psychiatric Association; May 18–23, 2002.
29.
BurtonS.Ziprasidone overdose [letter]. Am J Psychiatry.2000; 157: 835.
Haldol [package literature].Ortho-McNeil Pharmaceutical, Inc.; August 2000.
32.
MeltzerH.Y.Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry.2002; 63(suppl 9): 25–9.
33.
KatzR.FDA approval letter for NDA 20–919. FDA. June 21, 2002. (www.fda.gov) Accessed June 24, 2002.
34.
ZimbroffD.L.Safety and tolerability of IM ziprasidone: Review of clinical trial data [abstract]. Philadelphia: 155th Annual Meeting of the American Psychiatric Association; May 18–23, 2002.
35.
WilnerK.D.Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol.2000; 49(suppl 1): 43S–7S.
36.
MiceliJ.J.The effects of ketoconazole on ziprasidone pharmacokinetics: A placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol.2000; 49(suppl 1): 71S–6S.
37.
MiceliJ.J.The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol.2000; 49(suppl 1): 65S–70S.
38.
WilnerK.D.The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol.2000; 49(suppl 1): 57S–60S.
39.
MuirheadG.J.Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol.2000; 49(suppl 1): 49S–56S.
40.
ApseloffG.The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol.2000; 49(suppl 1): 61S–4S.
